[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rush University Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":646},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,56,0,25,[9,43,70,93,123,152,180,201,223,247,278,301,326,358,381,404,430,452,477,499,520,544,564,588,626],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100525366","phase-2-esomeprazole-and-radiation-induced-esophagitis-100525366",false,"NCT06120803","Esomeprazole and Radiation Induced Esophagitis","Effect of Esomeprazole on Radiation Induced Esophagitis in Non-small Cell Lung Cancer (EERENs): A Phase II Single Arm Study","EERENs","Inclusion Criteria:\n\n* Patient is ≥ 18 years of age.\n* Patient or patient's legal representative is willing and able to provide written informed consent and HIPAA authorization prior to performance of any study related activity.\n* Patient is willing and able to comply with scheduled visits and treatment schedules.\n* Patient has histopathologically confirmed diagnosis of NSCLC clinical stage III (as per the 8th edition of American Joint Committee on Cancer Staging).\n* Patients will receive thoracic radiation with estimated maximum dose to esophagus of at least 30 Gy (EQD2) in combination with concomitant chemotherapy.\n* Patient has Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.\n* Women of childbearing potential (WOCBP) must have a negative pregnancy test (serum or urine HCG) within 2 weeks of enrollment).\n* Double inclusion in any ongoing trial (if the other trial permits) will be allowed.\n\nExclusion Criteria:\n\n* Patient has history of gastroesophageal junction or stomach cancer.\n* Patient has history of pre-existing severe or very severe dysphagia.\n* Patient has history of severe liver disease, acute or subacute systemic lupus erythematosus.\n* Patient has interstitial nephritis.\n* Patient has history of peptic ulcer disease.\n* Patient has prior history of upper gastrointestinal bleeding.\n* Patient has a history of thoracic radiotherapy within 2 years of enrollment.\n* Patient has known or suspected allergic response and prior adverse drug reaction with proton pump inhibitors.\n* Patient is currently on clopidogrel, nelfinavir, rilpivirine, methotrexate, rifampin, digoxin, tacrolimus, or phenytoin as these may have major drug interaction with esomeprazole.\n* Patients without concomitant chemoradiotherapy and with estimated maximum dose to esophagus of less than 30 Gy (EQD2).","ALL","18 Years",{"count":21,"type":22},48,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Thoracic radiation therapy combined with chemotherapy (with or without immunotherapy) is the cornerstone of management in patients with locally advanced non-small cell lung cancer (NSCLC).",[28,29],"Radiation Esophagitis","Locally Advanced Lung Carcinoma","RECRUITING","2026-08-12",{"date":33,"type":34},"2026-08-14","ACTUAL",{"date":36,"type":34},"2024-03-01",{"date":38,"type":22},"2028-06-30",{"name":40,"class":41},"Rush University Medical Center","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":18,"minAge":19,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100369773","hip-arthroscopy-postoperative-opioid-demands-100369773","NCT04094701","Hip Arthroscopy Postoperative Opioid Demands","Randomized Control Trial Evaluating Postoperative Opioid Demands Following Hip Arthroscopy","Inclusion Criteria:\n\n* Adult patients age 18-80 years\n* English speaking\n* Opioid naive patient (defined as not taking opioid pills within 6 weeks prior to surgery), confirmed by checking the Illinois Prescription monitoring program\n* Primary hip arthroscopy\n* Written and informed consent for study participation\n\nExclusion Criteria:\n\n* Minors (\\\u003C18 years of age)\n* Opioid tolerant patients\n* Revision surgery\n* Prior infections of the operative joint\n* History of active malignancy within the past 5 years\n* Chronic pain conditions including low back pain, chronic pain syndrome, fibromyalgia\n* History of alcohol or other substance use disorder\n* Other disease states including rheumatologic conditions, diabetes mellitus, hypo\u002Fhyperthyroidism, depression, anxiety\n* Grade IV chondral defects",true,"80 Years",{"count":53,"type":22},170,[55],"NA","This study will be a prospective, single-blinded, randomized controlled trial (RCT), investigating the influence of the number of opioid pills prescribed following primary hip arthroscopy. All patients who sign the consent form will be enrolled in the suited and randomized to one of the two treatment arms. The intervention group will receive 5 Norco pills, gabapentin (30 mg, once daily for 10 days following surgery), and Tylenol (1000 mg, three times daily for 10 days following surgery) while the control will receive the standard at our practice of 30 Norco pills.",[58,59,60,61],"Opioid Use","Pain","Femoral Acetabular Impingement","Labral Tear, Glenoid","2026-08-11",{"date":64,"type":34},"2026-08-13",{"date":66,"type":34},"2020-10-21",{"date":68,"type":22},"2028-03",{"name":40,"class":41},{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100509833","postextubation-use-of-noninvasive-respiratory-support-in-severely-obese-patients-100509833","NCT05918575","Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients","A Randomized Controlled Trial of Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients","Inclusion Criteria:\n\n1. Adult, age ≥ 18 years old\n2. Receiving invasive mechanical ventilation for ≥24 hours\n3. BMI ≥40 kg\u002Fm2\n4. Undergoing planned extubation per treating team\n5. Arterial pH ≥7.35 or venous pH ≥ 7.31 within 30 mins of spontaneous breathing trial (SBT)\n\nExclusion Criteria:\n\n1. Pregnant\n2. Use of extra-corporeal membrane oxygenation\n3. Chronic tracheostomy in place\n4. Unplanned or accidental extubation\n5. Terminal\u002Fcompassionate extubation\n6. Contraindication to NIV use\n7. Intubated because of an acute exacerbation of COPD\n8. Underlying neuromuscular disease\n9. No reintubation requested by patient\u002Ffamily\n10. Documented\u002Fknown history of chronic hypercapnic respiratory failure on home NIV (including bilevel PAP).\n11. Enrolled in any other outcome study\n12. Treating clinician feels that HFNC or NIV are either mandatory or contraindicated for a given patient",{"count":78,"type":22},250,[55],"Around 20% of the obese patients with higher body mass index (BMI) who are taken off the breathing tube and breathing machine (ventilator) end up needing it back to support breathing. The re-application of breathing tube is associated with poor outcomes, including high risk of pneumonia, longer hospital stays, and death. The purpose of this study is to assess if prophylactic use of noninvasive breathing support after removing the breathing tube lowers the chance of needing the breathing tube again.",[82,83],"Obesity, Morbid","Extubation Failure","2026-08-04",{"date":86,"type":34},"2026-08-07",{"date":88,"type":34},"2023-07-10",{"date":90,"type":22},"2028-12-01",{"name":40,"class":41},5,{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":50,"sex":18,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":105,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":42},"100562868","end-diagnostic-overshadowing-100562868","NCT06608758","End Diagnostic Overshadowing","End Diagnostic Overshadowing: Understanding and Reducing Diagnostic Error in Patients With Disabilities","EDO","Inclusion Criteria:\n\n• Patients aged 3-89 who received billed charges\n\nExclusion Criteria:\n\n* Patients under age 3 or over age 89.\n* Patients with secondary diagnosis of dementia as the population is already known to be at increased risk of diagnostic error","3 Years","89 Years",{"count":104,"type":22},120000,"4 Years","OBSERVATIONAL","The goal of this study is to address the critical issue of diagnostic overshadowing by applying the Collective Impact Model40 to co-produce our End Diagnostic Overshadowing program with academic, health systems, health professional, PWDs, family members, and community stakeholders. Through this work, we will identify and address mechanisms that contribute to diagnostic overshadowing and diagnostic errors among people with disabilities. The main questions to answer are whether knowledge about diagnostic errors and confidence will improve with health care providers and professionals involved in diagnostic provesses, whether developed algorithms to identify patients at risk of diagnpstic error will be used, whether there will be change in time to diagnostic evaluation for PWD from the specified 5 population groups and with the specified diagnoses prone to error, and whether changes in usage of CPT Evaluation and Management codes will occur.",[109],"Disabilities Multiple",[111,112,113,114],"Disabilities","Diagnostic error","Diagnostic overshadowing","Algorithms","2026-08-03",{"date":117,"type":34},"2026-08-05",{"date":119,"type":34},"2024-11-22",{"date":121,"type":22},"2029-07-31",{"name":40,"class":41},{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":42},"100505643","phase-1-2r6r-hydroxynorketamine-for-the-treatment-of-neuropathic-pain-100505643","NCT05864053","(2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain","(2R,6R)-Hydroxynorketamine a Novel Therapeutic Analgesic for the Treatment of Neuropathic Pain: A Randomized Double Blind Cross-Over Trial.","HNK","Inclusion Criteria:\n\n* Adult patients (18 to 75 years) with an established diagnosis of chronic (\\> 3 month) NP of the extremities.\n* Presence of NP as determined at screening using the 10 item Neuropathic Pain Questionnaire (DN4), with a score of ≥4 required for study inclusion.\n* Ability to read and write English sufficiently to complete study related procedures.\n* A body mass index (BMI) (weight \\[kg\\]\u002Fheight\\[m \\]) between 18 and 35 kg\u002Fm (inclusive) and weighs between 50 kg and 120 kg (110 - 264 pounds).\n* Blood pressure with subject is in a supine position for approximately 5 minutes between 90 and 145 mmHg systolic and no higher than 90 mmHg diastolic at baseline.\n* A 12-lead ECG with no clinically significant abnormality as judged by the Investigator and QTc interval ≤ 450 milliseconds at baseline.\n* Resting pulse rate between 45 and 100 beats per minute.\n* Clinical laboratory findings and liver function tests within the normal range, or if outside of the normal ranges, deemed not clinically significant in the opinion of the PI.\n* Agree to provide written informed consent and comply with the rules regarding consumption of alcohol, caffeinated beverages, and tobacco\u002Fnicotine products during the study.\n* Patients may be taking scheduled or as needed medications for their chronic neuropathic pain and agree to continue taking the scheduled medications throughout the study period.\n* If the subject experiences pain relief they may elect not to take as needed medications.\n\nExclusion Criteria:\n\n* Subjects with suspected increased intracranial or intraocular pressure.\n* Subjects that have previously received ketamine for the treatment of a chronic pain diagnoses.\n* Previous or current participation in any clinical study with an investigational drug, device, or biologic within 30 days.\n* Subjects with severe medical illness including (but not limited to) hepatic, cardiovascular, pulmonary, renal, hematologic, endocrine, gastrointestinal, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease that in the opinion of the PI would endanger the safety of the subject or the validity of the study results.\n* Clinically significant acute illness in the 2 weeks prior to dosing.\n* Inability to effectively communicate with research staff.\n* Subjects with known liver disease.\n* Widespread pain or a diagnosis of fibromyalgia.\n* Current diagnosis of mental illness.\n* Pregnancy.\n* Allergy to ketamine or any study drug.\n* Consumption of beverages or food that contain alcohol, grapefruit, poppy seeds, Brussel sprouts, pomegranate, broccoli, char-grilled meat within 2 days prior to drug administration.\n* Use of tobacco or nicotine-containing products within 4 weeks prior to drug administration.\n* Poor peripheral venous access.\n* Subjects in the opinion of the PI should not participate in the study.","75 Years",{"count":7,"type":22},[134,25],"PHASE1","The goal of this randomized double blind three way (1:1:1) cross over clinical trial is to evaluate the effectiveness and duration of analgesia of a single infusion of (2R,6R)-HNK 0.5mg\u002Fkg compared with ketamine 0.5mg\u002Fkg and saline with a 5-week interval between treatments on pain, pain qualities, physical function, pain interference, sleep disturbance and quality of life in subjects with neuropathic pain of the extremities.\n\nThe questions that this study will address are:\n\n1. What is the analgesic efficacy of (2R,6R)-HNK on pain intensity and pain qualities in patients with chronic (\\>3 month) neuropathic pain (NP).\n2. What will be the effective duration of a single infusion of (2R,6R)-HNK in patients with NP.\n3. Will (2R,6R)-HNK reduce pain related effects including interference in daily activities of life, sleep disturbances and change the qualities of pain reported by patients.\n\nParticipants will receive each of the three study drugs in a random order at 5-week intervals over a 15 week period. The drug will be administered as a 45-minute infusion.\n\nParticipants will complete quantitative sensory and pain evaluations and complete patient reported pain outcomes prior to receiving the first study drug and at 7, 14 and 21 and 35 days following study drug administration.",[137],"Pain, Neuropathic",[139,140,141,142,143,144],"pain","pain, chronic","pain, neuropathic","non-opioid analgesic","ketamine","(2R,6R)-hydroxynorketamine","2026-07-30",{"date":115,"type":34},{"date":148,"type":34},"2024-09-19",{"date":150,"type":22},"2027-08",{"name":40,"class":41},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":4},"100584850","phase-4-oral-tranexamic-acid-after-total-knee-arthroplasty-100584850","NCT06894719","Oral Tranexamic Acid After Total Knee Arthroplasty","Prolonged Oral Tranexamic Acid Use in Primary Total Joint Arthroplasty: A Double Blind Randomized Placebo Controlled Trial","Inclusion Criteria:\n\n* Any patient undergoing primary TKA at Rush main hospital or participating ASC\n* Willingness to undergo randomization to take medication potentially up to 7 days post op.\n* Willing to answer daily questions on pain, functionality and opioid consumption\n\nExclusion Criteria:\n\n* History of venous thromboembolism, MI, or stroke in the past year\n* Patients on any chronic anticoagulation medications besides Aspirin\n* Patients with Cancer\n* Patients with end stage renal disease that are on dialysis\n* Drug allergy to TXA\n* Taking oral birth control\n* Unable to provide consent",{"count":160,"type":22},351,[162],"PHASE4","This is a prospective, double-blind, randomized controlled trial evaluating the efficacy of oral tranexamic acid (TXA) in total knee arthroplasty (TKA). The study will assess pain, function, and range of motion (ROM) over a 2-year period, with key evaluations at 6 weeks and 90 days postoperatively.\n\nHypothesis:\n\nPatients receiving 1.95g oral TXA for 3 or 7 days post-op will show improved pain, function, and ROM at 6 weeks and 90 days, with similar blood loss and transfusion rates as the control group.",[165],"Total Knee Arthroplasty",[167,168,169,170],"tranexamic acid","range of motion","postoperative pain","postoperative function","NOT_YET_RECRUITING","2026-07-21",{"date":174,"type":34},"2026-07-23",{"date":176,"type":22},"2026-09-01",{"date":178,"type":22},"2027-05-01",{"name":40,"class":41},{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":51,"enrollmentInfo":187,"targetDuration":189,"studyType":106,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":42},"100580349","biomarkers-for-cognitive-decline-in-intracerebral-hemorrhage-100580349","NCT06836141","Biomarkers for Cognitive Decline in Intracerebral Hemorrhage","Silent Brain Infarcts in Spontaneous Intracerebral Hemorrhage as a Prognostic Biomarker for Vascular Contributions to Cognitive Impairment and Dementia (VCID)","Inclusion Criteria:\n\n* Primary Intracerebral Hemorrhage\n* Age ≥ 18 and \\\u003C 80 years\n\nExclusion Criteria:\n\n* Pre-existing dementia",{"count":188,"type":22},118,"12 Months","The goal of this clinical trial is to see if silent brain infarcts (SBIs), or stroke-like symptoms detectable during brain imaging, are a possible contributor to cognitive decline for patients diagnosed with spontaneous intracerebral hemorrhage (sICH), or blood clot in the brain. The main questions it aims to answer are\n\n* if SBIs in sICH are associated with a lower cognitive level and more rapid cognitive decline\n* if SBIs in sICH are associated with certain findings on brain imaging\n* if SBIs in sICH are associated with higher inflammation measured by certain blood tests\n\nParticipants will undergo\n\n* cognitive testing during hospitalization, and at 3, 6 and 12 months after the sICH\n* Magnetic Resonance Imaging (MRI) of the brain during hospitalization and 12 months after the sICH\n* blood draws during hospitalization and at 3, 6 and 12 months after the sICH",[192],"Primary Intracerebral Hemorrhage","2026-07-10",{"date":195,"type":34},"2026-07-13",{"date":197,"type":34},"2025-08-02",{"date":199,"type":22},"2029-08-01",{"name":40,"class":41},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":42},"100615106","primary-care-strategies-for-weight-management-prism-study-100615106","NCT07288294","PRImary Care Strategies for Weight Management (PRISM) Study","Primary-Care Strategies to Enhance Weight Management (PRISM) After Discontinuation of Anti-Obesity Medications","PRISM","Inclusion Criteria:\n\n1. For run-in: prescribed liraglutide, semaglutide, or tirzepatide or newer medication approved by the FDA for long-term use for obesity treatment for the purpose of weight managment by a primary care provider at Rush University System for Health and have received at least one dose of the medication concurrent with enrollment in the study.\n2. For randomization: discontinue their prescribed anti-obesity medication.\n3. Age 18+\n\nExclusion Criteria:\n\n1. Not fluent in English\n2. Diagnosis of diabetes (type 1 or type 2)\n3. Current or planned pregnancy\n4. Bariatric surgery in the past 2 years or planned bariatric surgery.\n5. Body mass index ≥60 kg\u002Fm2, due to increased injury risk with exercise\n6. Body weight ≥ 375 pounds (scale capacity with a margin for regain)\n7. No access to home WIFI or a smartphone with data available\n8. Medical contraindications to treatment, including significant cognitive impairment, active substance abuse based on the World Health Organization's ASSIST screener, or serious medical illness (e.g., stage 3 or 4 heart failure, cancer, renal failure, etc.)\n9. Concurrent engagement with other behavioral treatments for obesity (for randomized phase only).\n10. Medication obtained from online\u002Fcompound pharmacies or prescription from specialty clinic without a prescription from primary care team at the time of enrollment\n11. Another member of the household is enrolled in the study",{"count":210,"type":22},214,[55],"The goal of this clinical trial pilot is to determine the feasibility of an intervention to enhance weight management in patients who have stopped taking anti-obesity\u002Fweight management medications in primary care. The main questions it aims to answer are:\n\n* Can patients be recruited into the study efficiently?\n* Is the program acceptable to patients?\n* Can the study be conducted efficiently?\n\nThe new program will be compared to usual care.",[214],"Obesity","2026-07-07",{"date":217,"type":34},"2026-07-09",{"date":219,"type":34},"2026-06-04",{"date":221,"type":22},"2028-04-01",{"name":40,"class":41},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":50,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":42},"100446787","phase-4-medrol-dosepak-for-outpatient-total-knee-arthroplasty-100446787","NCT05097976","Medrol Dosepak for Outpatient Total Knee Arthroplasty","An Oral Methylprednisolone Taper Within a Multimodal Analgesic Regimen After Total Knee Arthroplasty: a Double-Blind Randomized Placebo-Controlled Trial","Inclusion Criteria:\n\n* Any patient undergoing primary TKA with a diagnosis of osteoarthritis\n\n  •≥ 18 years old\n* Willingness to undergo randomization\n\nExclusion Criteria:\n\n* Reported chronic corticosteroid or opiate use\n* Suspected or confirmed periprosthetic joint infection\n* Revision TKA\n* Primary diagnosis other than osteoarthritis, including avascular necrosis, fracture, or post-traumatic arthritis\n* American Society of Anesthesiologists (ASA) score ≥ 4\n* Reported history of liver disease, renal disease, or diabetes mellitus\n* Current systemic fungal infection or other local infection\n* Immunocompromised or immunosuppressed\n* Current peptic ulcer disease\n* History of hypothyroidism, psychosis, heart failure, myasthenia gravis, ocular herpes simplex virus, or systemic sclerosis\n* Women with reported current pregnancy\n* Known hypersensitivity to methylprednisolone\n\n  •≤ 18 years old\n* Inability to take oral medications\n* Unable to provide consent",{"count":231,"type":22},420,[162],"The purpose of this study is to evaluate the efficacy of an oral methylprednisolone taper on acute postoperative pain, function, opioid consumption, nausea, and complications following outpatient total knee arthroplasty (TKA). We hypothesize that administration of an oral methylprednisolone taper starting on postoperative day 1 (POD 1) following TKA will be associated with improved pain and decreased opioid use, nausea, and complications at POD1-7, as compared to similar patients who receive placebo. Additionally, those taking methylprednisolone will report decreased pain and greater objective functional outcomes at 3 and 6 weeks postoperatively as compared to controls.",[165],[236,237,238,239,240],"Methylprednisolone","acute postoperative pain","acute function","opioid consumption","complications following total knee arthroplasty",{"date":217,"type":34},{"date":243,"type":34},"2022-03-01",{"date":245,"type":22},"2027-12",{"name":40,"class":41},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":255,"minAge":19,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":258,"briefSummary":259,"conditions":260,"keywords":265,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":42},"100630405","phase-2-paracervical-block-with-combined-ketorolac-and-lidocaine-for-osmotic-dilator-placement-100630405","NCT07487246","Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement","Effects of Paracervical Block With Combined Ketorolac and Lidocaine on Perceived Pain in Osmotic Dilator Placement for Abortion, a Randomized Controlled Trial","PCB-KinD","Inclusion criteria:\n\nAge \\>\u002F= 18 years English or Spanish speaking Ability and willingness to sign the informed consent Ability and willingness to comply with the terms of the study including possessing active cell phone with text messaging capabilities Voluntary request for pregnancy termination Ultrasound-confirmed intrauterine pregnancy with an estimated gestational age of 16+0-23+6 weeks gestational age Require osmotic dilator placement one day prior to procedural abortion according to institutional protocol Seeking outpatient abortion services at Rush University Medical Center\n\nExclusion criteria:\n\nHave taken NSAIDs less than 6 hours prior to their clinic visit Contraindications to lidocaine such as allergy to lidocaine, cardiac arrhythmia or heart block, and porphyria Allergic reaction or sensitivity to NSAIDs History of peptic ulcer or gastrointestinal bleed, history of gastric bypass (RYGB) or recent history in last 6 months of gastric sleeve; history of inflammatory bowel disease (Ulcerative colitis, Crohn's disease) Uncontrolled hypertension, heart failure, ischemic heart disease, peripheral arterial disease, cerebrovascular disease Acute renal failure or chronic renal disease Chronic liver disease History of bleeding diathesis Untreated acute cervicitis or pelvic inflammatory disease Require or request PO benzodiazepine or IV sedation for placement of osmotic dilators Require more than 1 day of osmotic dilators Chronic or current narcotic use Current recreational drug use (excluding cannabis) Require transabdominal\u002Ftransvaginal injection for induced fetal demise prior to abortion","FEMALE",{"count":257,"type":22},76,[25],"The purpose of this study is to improve pain management for participantswho need osmotic dilators for cervical preparation the day before their second trimester abortion procedure.",[261,262,263,264],"Pain Management","Abortion","Second Trimester Abortion","Dilation and Evacuation",[266,267,268,269],"randomized controlled trial","osmotic dilators","ketorolac","paracervical block","2026-07-01",{"date":272,"type":34},"2026-07-06",{"date":274,"type":34},"2026-06-29",{"date":276,"type":22},"2027-04-30",{"name":40,"class":41},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":291,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":300,"locationsCount":42},"100593366","automatic-tube-compensation-vs-pressure-support-ventilation-during-spontaneous-breathing-trials-in-adults-100593366","NCT07005505","Automatic Tube Compensation vs. Pressure Support Ventilation During Spontaneous Breathing Trials in Adults","Automatic Tube Compensation vs. Pressure Support Ventilation During Spontaneous Breathing Trials in Critically Ill Adults: A Cluster-Randomized, Cluster-Crossover Trial","Inclusion Criteria:\n\n* Admitted to intensive care unit (ICU)\n* Age 18 years or older\n* Requiring invasive mechanical ventilation for at least 24 hours\n* Pass spontaneous breathing trial screen criteria\n\nExclusion Criteria:\n\n* Clinical decision made not to proceed with extubation regardless of spontaneous breathing trial (SBT) results\n* Do not intubate (DNI) order\n* Presence of tracheostomy\n* Pregnancy\n* Known prisoner\n* Immediate need for extubation, self-extubation, or unplanned extubation that precludes safe performance of study procedures\n* Enrolled in another clinical trial that impacts ventilator weaning or liberation",{"count":286,"type":22},880,[55],"For patients requiring mechanical ventilation, spontaneous breathing trials (SBTs) are conducted to determine if it is safe to remove the breathing tube. There are multiple methods for conducting SBTs. The purpose of this study is to compare the effects of 2 methods, pressure support ventilation (PSV) versus automatic tube compensation (ATC), on successful extubation for critically ill adult patients who received mechanical ventilation for over 24 hours.",[290],"Spontaneous Breathing Trial in ICU",[292,293],"Ventilator liberation","Spontaneous breathing trial","2026-06-30",{"date":296,"type":34},"2026-07-02",{"date":298,"type":34},"2025-06-01",{"date":150,"type":22},{"name":40,"class":41},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":308,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":316,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":42},"100603888","synovial-fluid-withdrawal-or-prp-injection-for-acute-acl-tears-and-cytokines-100603888","NCT07142369","Synovial Fluid Withdrawal or PRP Injection For Acute ACL Tears and Cytokines","Does Arthrocentesis and PRP For Acute ACL Tears With Hemarthrosis Decrease Inflammatory Cytokines At Time Of Surgery: A Prospective Randomized Control Trial (RCT)","Inclusion Criteria:\n\n* Age 18 - 50\n* English-speaking\n* Clinical evidence of ACL rupture with swelling\n* Participant must be undergoing ACL reconstruction surgery\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>50\n* Presentation \\>3 weeks after initial injury\n* Previous traumatic ipsilateral (same side) knee injury consistent with chronic ACL tear or prior ACL surgery\n* \\> Kellgren-Lawrence grade 2 changes on preoperative x-ray\n* History of hemophilia or inflammatory arthropathy (e.g., rheumatoid arthritis)","50 Years",{"count":310,"type":22},99,[55],"The purpose of this study is to determine what effects the withdrawal of excess knee joint fluid or the injection of a factor from the blood has on swelling after a sudden anterior cruciate ligament (ACL) rupture of the knee.",[314,315],"Posttraumatic Osteoarthritis","Anterior Cruciate Ligament (ACL) Rupture",[317],"osteoarthritis","2026-06-17",{"date":320,"type":34},"2026-06-18",{"date":322,"type":22},"2026-09",{"date":324,"type":22},"2028-12",{"name":40,"class":41},{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":337,"conditions":338,"keywords":342,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":42},"100594505","phase-2-brain-computer-interface-visualization-training-to-optimize-muscle-activation-following-orthopaedic-surgery-100594505","NCT07020312","Brain-Computer Interface Visualization Training to Optimize Muscle Activation Following Orthopaedic Surgery","Brain-Computer Interface Visualization Training to Optimize Muscle Activation Following Orthopaedic Surgery: A Blinded Randomized Controlled Trial","iBrainTechRCT","Participants\n\n* Inclusion Criteria:\n\n  * Patient age \\>18 years\n  * Ability to complete neurofeedback training and follow study follow-ups\n  * Indicated for one of the four investigated orthopedic procedures\n* Exclusion Criteria:\n\n  * Inability to participate in neurofeedback training\n  * Lack of decisional capability\n  * History of stroke, movement disorder (e.g. Parkinson's), peripheral neuropathy\n  * Cardiac pacemaker or other internal electronic device\n  * BMI \\>35\n  * Previous surgery or specific pathology on the affected joint (refer to procedure specific indications below)\n\nProcedure Specifics:\n\nAnterior cruciate ligament reconstruction (ACLR) Procedure-specific Inclusion Criteria\n\n* Patients undergoing primary ACLR with autograft or allograft tissue\n* Adjunct lateral Extra-articular tenodesis will be included\n* Additional meniscus debridement and repair will be included Procedure-specific exclusion criteria\n* Revision ACL surgery\n* Moderate to Severe arthritis - Kellgren-Lawerence (KL) Grade \\> 3\n* Patients with meniscus root repair\n* Non-weight-bearing status exceeding 1 week postoperatively\n\nTotal knee arthroplasty (TKA) Procedure specific inclusion criteria\n\n* Patients undergoing primary TKA\n* Preoperative total knee range of motion of at least 100 degrees (combined flexion and extension)\n* Prior extensor mechanism tendon repair, quadriceps or patella tendon. Procedure specific exclusion criteria\n* Revision surgery\n* Hinged implant\n* Any open procedure involving the knee joint\n* Symptomatic arthritis in the contralateral knee with planned or expected total knee arthroplasty within 6 months\n* Inflammatory Arthritis\n\nTotal hip arthroplasty (THA) Procedure Specific Inclusion Criteria\n\n* Patients undergoing primary THA Procedure Specific Exclusion Criteria\n* Revision Surgery\n* Any open procedure involving the hip joint\n* Bilateral THA procedures\n* Inflammatory Arthritis\n\nHip arthroscopy (HA) for femoroacetabular impingement syndrome (FAIS) Procedure Specific Inclusion Criteria\n\n· Patients undergoing HA for FAIS Procedure Specific Exclusion Criteria\n\n* Revision Surgery\n* Diagnosis of hip dysplasia",{"count":335,"type":22},240,[25],"After orthopedic surgeries like knee or hip replacement, some patients struggle to fully activate their muscles due to a condition called Arthrogenic Muscle Inhibition (AMI). AMI can slow recovery and make physical therapy less effective. This clinical trial is testing whether a special type of brain training-called neurofeedback visualization training-can help improve muscle activation and speed up recovery.\n\nIn this study, patients will receive standard physical therapy after surgery. Half of them will also use a device that helps them \"visualize\" exercises while wearing a cap that reads brain signals (EEG). The cap tracks brain activity when patients imagine doing specific movements. A computer then shows a virtual avatar performing the movements, giving feedback in real time-like a video game controlled by the brain.\n\nThe study includes patients recovering from one of four surgeries:\n\n1. Anterior cruciate ligament reconstruction (ACLR)\n2. Total knee arthroplasty (TKA)\n3. Total hip arthroplasty (THA)\n4. Hip arthroscopy (HA) for femoroacetabular impingement (FAI)\n\nThe goal is to see if this training improves muscle strength, movement, and daily function more than standard therapy alone. The study will take place at Rush University Medical Center in Chicago and enroll 240 adults, with 60 patients per type of surgery. Each participant will be followed for up to 6 months after surgery and complete strength tests, movement assessments, and questionnaires about their recovery.\n\nThe hope is that combining brain training with physical therapy will lead to faster, more complete recoveries and improve how patients move after surgery.",[339,340,165,341],"Anterior Cruciate Ligament Reconstruction","Total Hip Arthroplasty (THA)","Hip Arthroscopy",[343,344,345,341,346,347,348,349,350,351],"ACLR","THA","TKA","Arthrogenic muscle inhibition","Electroencephalography","Gait","Motion Analysis","Biomechanics","Strength",{"date":320,"type":34},{"date":354,"type":34},"2025-08-14",{"date":356,"type":22},"2028-08-01",{"name":40,"class":41},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":50,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":23,"phases":368,"briefSummary":369,"conditions":370,"keywords":372,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":42},"100614655","phase-1-behavioral-economic-attributes-of-recreation-100614655","NCT07282418","Behavioral Economic Attributes of Recreation","Behavioral Economic Attributes of Recreation (BEAR): A Pilot Trial Within a Ccohort","BEAR","Eligibility criteria for BEAR main cohort enrollment (N=120):\n\n* Age 18 years or older\n* Fluent in English\n* Lives within 10 miles of the study site\n* Not planning to move outside the study region in the next 6 months\n* Has a working Android or iOS mobile device they are willing to use for EMA surveys and communication with the study team\n* No apparent cognitive deficits that would suggest a lack of capacity to consent or complete study procedures\n* No uncontrolled serious mental illness, marked by an inpatient hospitalization, increase or change in antipsychotic or mood stabilizing medication, or suicidal intent in the past 6 months.\n\nEligibility for selection into the RCT component (n=60):\n\n* At least 75% adherence to EMA surveys during the initial assessment\n* Complete baseline data within the observational cohort component\n* Participant endorses engagement in recreation less than 4 times per week based on EMA surveys\n* LE8 score \\\u003C70, reflecting low to moderate cardiometabolic health.\n* No serious substance abuse problem based on an ASSIST score of ≥27 for any substance other than tobacco or cannabis\n* Willing and able to try recreational activities for the next 6 months",{"count":367,"type":22},120,[134,25],"Risk for developing and dying from heart disease, type 2 diabetes, stroke, and other cardiometabolic conditions is strongly influenced by behavioral risk factors, including poor diet, physical inactivity, and tobacco and alcohol abuse. Behavioral economic models predict engagement in these behaviors as a function of their subjective value, ability to provide immediate gratification, and availability of competing alternatives. A key implication of the behavioral economic model is that increasing the accessibility of compelling alternative sources of reinforcement may displace engagement in unhealthy behaviors. Developing interventions that leverage these insights requires both a clear understanding of the characteristics of the \"reward landscape\" of U.S. adults, and the impact of altering the reward landscape on behavioral economic processes and health behavior.\n\nThis pilot study uses a trial within a cohort (TwiC) design to pursue these objectives. A representative sample of adults (N=120) will be enrolled into an observational cohort. Cardiometabolic health will be assessed and quantified based on the Life's Essential 8 (LE8) scoring system,4 which includes 4 behavioral (physical activity, diet quality, sleep, tobacco use) and 4 biomedical (non-HDL cholesterol, glucose, weight status, and blood pressure) factors. Structured home audit tools and an ecological momentary assessment (EMA) protocol will be used to measure environmental access to, demand for, and engagement in various rewarding activities, including different categories of recreational activity, electronic entertainment, social activities, and consumable rewards including food, tobacco products, and alcohol. The inter-relationships between different types of rewarding behaviors as substitutes or complements, and their links with cardiometabolic health, will be examined overall and with stratification by socioeconomic status.\n\nFollowing completion of the first assessment, a subset of participants will be selected for randomization to a recreation-focused intervention or continued observation within the cohort based on their baseline status and protocol adherence. In TwiC designs, the \"control\" group simply continues to complete observational assessments within the cohort and is not notified that an intervention is ongoing. The BEAR \"intervention\" group will be approached for consent to participate in a 6-month behavioral economic intervention in which recreational activities are promoted as a strategy to displace cardiometabolic risk behaviors. The scientific aims of the randomized trial component of the study include examining change in LE8 scores, demand for various rewarding activities, discounting rates, and health behaviors. BEAR will also address several feasibility aims, including demonstrating the ability to measure and categorize access to rewarding activities, document recreation-related expenditures by participants, and estimate intervention uptake and acceptability.",[371],"Cardiometabolic Health Indicators",[373],"recreation","2026-06-16",{"date":320,"type":34},{"date":377,"type":34},"2026-05-11",{"date":379,"type":22},"2027-06-30",{"name":40,"class":41},{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":23,"phases":389,"briefSummary":390,"conditions":391,"keywords":393,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":42},"100585237","e3-hypertension---a-team-based-multidisciplinary-model-in-addressing-barriers-to-hypertension-control-100585237","NCT06899750","E3 Hypertension - A Team-based, Multidisciplinary Model in Addressing Barriers to Hypertension Control","Inclusion Criteria:\n\n* Adults 18 years or older\n* African American and\u002For Latinx\n* Uncontrolled stage 2 hypertension, BP \\>\u002F= 140\u002F90\n* Patient is following with Rush primary care provider in eligible Rush primary care clinics\n* Patient has a smart phone (Android or iOS)\n* Patient has an email\n\nExclusion Criteria:\n\n* Organ transplant recipient\n* On dialysis\n* Patient is already participating in another remote hypertension monitoring program\n* Patient is not interested in participating in the program\n* Patient has already participated in the E3 Hypertension program or the E3 Diabetes program",{"count":388,"type":22},200,[55],"This study aims to compare a multidisciplinary clinical hypertension and social needs intervention to enhanced standard of care for hypertension management in primary care clinics with regards to hypertension control outcomes.",[392],"Hypertension",[394,395,396,397],"hypertension","self-monitoring","social determinants of health","adherence",{"date":320,"type":34},{"date":400,"type":34},"2025-02-10",{"date":402,"type":22},"2026-10-01",{"name":40,"class":41},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":23,"phases":414,"briefSummary":415,"conditions":416,"keywords":419,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":427,"leadSponsor":429,"locationsCount":42},"100627728","protocolized-weaning-of-high-flow-nasal-cannula-in-adult-patients-100627728","NCT07452406","Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients","Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients: A Stepped-Wedge Cluster Randomized Trial (PRO-WEAN HFNC)","PRO-WEAN HFNC","Inclusion Criteria:\n\n* Adult patients ≥ 18 years\n* Receiving HFNC for ≥12 hours\n* Receiving HFNC to treat acute hypoxemic respiratory failure, defined as requirement of FIO2 ≥ 0.5 to maintain SpO2 at 90-97% and Evidence of increased work of breathing at initiation (e.g., tachypnea with respiratory rate \\> 20-25\u002Fmin, or accessory muscle use), including:\n\n  * Patients using HFNC to avoid intubation\n  * Post-extubated patients who develop acute hypoxemic respiratory failure, regardless of respiratory support device prior to HFNC use.\n* The bedside clinical team determines that HFNC weaning is clinically appropriate\n* Demonstrates clinical stability, defined as:\n\n  * Respiratory rate ≤ 25 breaths per minute without use of accessory respiratory muscles\n  * SpO₂ \\> 90% on HFNC\n  * HFNC FiO₂ ≤ 0.80\n\nExclusion Criteria:\n\n* • Planned procedures requiring intubation\n\n  * Hypercapnia (PaCO2 ≥ 45 mmHg)\n  * Receiving extracorporeal membrane oxygenation (ECMO)\n  * Receiving continuous aerosol therapy via HFNC (e.g., inhaled nitric oxide \\[iNO\\], epoprostenol, or continuous albuterol)\n  * Receiving chronic home use of HFNC, CPAP, or noninvasive ventilation therapy to treat chronic respiratory failure\n  * Receiving HFNC as preventative post-extubation therapy, defined as HFNC use immediately after extubation for less than 48 hr in the absence of clinical signs of respiratory failure.",{"count":413,"type":22},2000,[55],"High-flow nasal cannula (HFNC) is a type of oxygen therapy commonly used in adults with breathing problems. While HFNC can help patients avoid breathing tubes and improve oxygen levels, there is no standard method for deciding how and when to reduce and stop this therapy once a patient improves. In many hospitals, these decisions vary from clinician to clinician.\n\nThis study will compare usual care with a standardized step-by-step plan for reducing HFNC support. Eight hospitals will participate and will switch from usual care to the standardized plan at different time points during the study.\n\nThe main goal is to determine whether the standardized weaning plan increases the number of patients who can successfully stop HFNC within 5 days. The study will also evaluate how long patients remain on HFNC, whether they need additional breathing support, and how long they stay in the hospital.\n\nThe results may help develop clearer guidance for safely and efficiently stopping HFNC therapy.",[417,418],"Acute Hypoxemic Respiratory Failure","High-Flow Nasal Cannula Therapy",[420,421,422],"High-flow nasal cannula","Acute hypoxemic respiratory failure","Weaning","2026-06-07",{"date":425,"type":34},"2026-06-10",{"date":176,"type":22},{"date":428,"type":22},"2028-06-28",{"name":40,"class":41},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":23,"phases":439,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":451},"100483773","a-randomized-crossover-trial-of-bright-light-therapy-in-crohns-disease-on-intestinal-barrier-homeostasis-100483773","NCT05579392","A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis","Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis","Inclusion Criteria:\n\n1. Biopsy proven diagnosis of Crohn's or Ulcerative Colitis\n2. 18 years or older\n3. Fecal Calprotectin \\> 50 or CRP above upper limit of normal or a PROMISE Fatigue ≥ 50\n4. Has been on a stable dose of either a biologic, immunomodulator, or 5-ASA for at least 12 weeks\n\nExclusion Criteria:\n\n1. Active IBD (Harvey Bradshaw Index \\> 5 or Modified Harvey Bradshaw Index \\>5)\n2. Major depression (score ≥ 21 or any endorsement of suicidal intent on the Beck Depression)\n3. Sleep apnea (score high risk in 2 or more categories of the Berlin Questionnaire) (43)\n4. Restless leg syndrome (score ≥ 15 on the IRLS Study Group Rating Scale(44))\n5. Regular use of medications that affect intestinal permeability, and\u002For endogenous melatonin including metoclopramide, NSAIDs, beta blockers, psychotropic medications, hypnotics and exogenous melatonin products during 4 weeks prior to the study\n6. People who have worked night shifts or crossed more than 2 time zones in the previous month\n7. Any major organ disease - renal impairment (creatinine\\>1.2 mg\u002FdL), diabetes (Hgb-A1c \\> 6.5%); liver disease (LFTs \\> 1.5x normal), or significant cardiac failure (NY classification stage III\u002FIV)\n8. Diagnosis of narrow angle glaucoma or retinal disorders or demonstrated symptoms indicative of these diagnosis during the eligibility screening\n9. Inability to sign an informed consent",{"count":438,"type":22},30,[55],"Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the most significant chronic conditions of the gastrointestinal tract (GIT) and affects over 1.5 million individuals in the U.S. Recently, there has been an increased understanding of the importance of sleep and sleep disruption in IBD as a potentially modifiable risk factor. We, therefore, hypothesize that intervening with morning bright light therapy (BLT) in IBD patients with CM will decrease intestinal permeability and pro-inflammatory cytokines, positively impact intestinal microbiota, and improve quality of life (QoL).",[442],"Inflammatory Bowel Disease","2026-06-05",{"date":445,"type":34},"2026-06-09",{"date":447,"type":34},"2022-09-22",{"date":449,"type":22},"2026-10-31",{"name":40,"class":41},2,{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":467,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":474,"leadSponsor":476,"locationsCount":42},"100621855","rush-food-is-medicine-veggie-rx---gusnip-produce-prescription-100621855","NCT07376044","RUSH Food is Medicine Veggie Rx - GusNIP Produce Prescription","GusNIP Produce Prescription Project","Inclusion Criteria:\n\n* Adults over 18 years of age\n* Participants receiving medical care at Rush\n* Participants with a diagnosis of hypertension and\u002For diabetes\n* Participants with a positive screen for food insecurity\n* Participants eligible for medical assistance through a state plan\n* Participants eligible for benefits through the SNAP program\n* Participants are member of a low-income household\n* Participants willing to participate for duration of the program (12-months)\n* Participants residing in service area of the referring Rush clinic\n\nExclusion Criteria:\n\n* Adults unable to consent\n* Individuals not yet adults - infants, children, teenagers\n* Incarcerated individuals",{"count":460,"type":22},400,[55],"The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and\u002For diabetes. The main questions it aims to answer are:\n\n* Does participation increase fruit and vegetable consumption for participants?\n* Does participation reduce individual and household food insecurity?\n* Does participation reduce healthcare utilization and associated costs?\n* Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)?\n* Does participation support the local economy by increasing participant spending at local food vendors?\n\nParticipants will:\n\n* Receive 6 months home delivered produce prescription boxes\n* Receive 6 months match of produce vouchers\n* Receive nutrition education and participate in Chronic Disease Self-Management classes",[464,465,466],"Food Insecurity","Diabetes in Adults","Hypertension (HTN)",[464,468,469,470,471],"Food is Medicine","Nutrition Security","Diet-related Chronic Disease","Produce Prescription",{"date":443,"type":34},{"date":294,"type":22},{"date":475,"type":22},"2028-09",{"name":40,"class":41},{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":50,"sex":18,"minAge":484,"maxAge":131,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":487,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":42},"100526782","gut-microbiota-mediated-inflammatory-interactions-between-aud-and-hiv-infection-100526782","NCT06139224","Gut Microbiota-Mediated Inflammatory Interactions Between AUD and HIV Infection","Gut Microbiota-Mediated Inflammatory Interactions Between Alcohol Use Disorders and HIV Infection","Inclusion Criteria:\n\n* Age 21 to 75 years men and women\n* Infection with HIV-1, as documented by a licensed ELISA and confirmed by a Western blot or HIV-1 RNA\n* On ART for at least 12 months. No history of zidovudine (AZT) or stavudine (D4T) use.\n* No change in ART for at least 6 months.\n* CD4+ T cell count of \\> 250 cells\u002Fµl, nadir CD4+ T cell count of \\> 250 cells\u002Fµl\n* Plasma HIV-1 RNA level consistently below the limit of detection of commercial ultrasensitive assay (usually \\\u003C20 copies\u002FmL) for at least six months before study entry.\n* For those for \"AUD group\" AUDIT-C =\u002F\\> 4 for men and = ≥3 for women.\n* Documented BMI between 25-40\n* Ability and willingness to provide informed consent\n\nExclusion criteria:\n\n* Receipt of a non-HIV vaccine within 30 days\n* Opportunistic infection within 30 days\n* Immunosuppressive medications (e.g., systemic corticosteroids, tacrolimus, sirolimus, mycophenolate, azathioprine, interferon, and cancer chemotherapy) within 90 days\n* History of clinically significant medical disease that could potentially impact the integrity of intestinal barrier function or microbiota including renal (creatinine \\>2 mg\u002FdL), liver (documented cirrhosis based on histology or ALT\u002FAST greater than 2 1\u002F2 times normal), cardiac failure (NY classification III\u002FIV), or uncontrolled diabetes (Hgb-A1c\\>8%).\n* Fiber intake \\> 15 grams.\n* Chronic HBV and un-treated HCV (documentation of cure can be enrolled)\n* Herbal\u002Fbotanical supplements with potential microbiome or anti-inflammatory effects (e.g., inulin\u002Fchicory fiber, berberine, high-dose polyphenols). Participants will be eligible to participant if they discontinue use for at least 2 weeks before enrollment.\n* Regular use of medications that affect intestinal permeability including NSAIDs (daily more than three days a week during the prior two weeks). Type and frequency and duration of NSAID (those taking less than 3 \u002Fper week) should be recorded. If participants need to take antibiotics or NSAIDS during the study, duration, name, and dosage will be recorded but they will not be excluded.\n* Antibiotics (during or prior) four weeks to enrollment. Type and duration of antibiotic treatment within 90 days should be recorded.\n* Current use of a restrictive or specialty diet like vegan, vegetarian, gluten-free, Paleo, or any specific carbohydrate diet because these diets can impact the microbiota community.\n* Use of herbal, botanical, or nutraceutical supplements with potential effects on the gut microbiome or systemic inflammation. This includes:\n\nprebiotic fibers such as inulin, chicory root, fructooligosaccharides (FOS), or galactooligosaccharides (GOS) botanical or herbal compounds with microbiome-modulating or anti-inflammatory properties, such as berberine, curcumin, resveratrol, or high-dose polyphenol Probiotics or synbiotics Digestive enzymes or other nutraceuticals reported to alter gut microbial composition.\n\nPotential participants may enroll if they discontinue use for at least 2 weeks before enrollment. Type, dosage, frequency, route of administration (for example oral), and date last taken will be documented at time of enrollment verify that a sufficient washout period has occurred before enrollment.\n\n-Have undergone bowel preparation or colonic (e.g., for a colonoscopy or similar procedure) for example, within 4 weeks prior to enrollment.\n\nInflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease). Celiac disease. GI cancers\n\n* Gastrointestinal surgeries\u002Fresection (cholecystectomy is accepted but should be recorded)\n* Currently taking or planning to start a GLP-1 receptor agonist or dual GLP-1\u002FGIP receptor agonist for weight loss or weight management. This includes medications such as semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), lixisenatide (Adlyxin), and tirzepatide (Mounjaro, Zepbound). Participants who previously used these medications may be eligible if they discontinued use at least 4 weeks prior to enrollment. For eligible individuals, the medication name, dosage, frequency, route of administration (for example injection or oral), and date of last dose will be documented at enrollment. The study team will document the last dose to verify that a sufficient wash out period has occurred before enrollment and to account for any possible microbiome differences.\n* Use of PPI is accepted but type, dose and duration should be recorded.","45 Years",{"count":486,"type":22},40,[55],"Alcohol use disorder (AUD) has been associated with high prevalence of inflammation-associated co-morbidities in people living with HIV even those receiving effective antiretroviral therapy (ART). Our preliminary data support a model in which the combined insult of AUD and HIV on the gut, specifically on the microbiota and intestinal barrier integrity, exacerbates inflammation. Our preliminary data using intestinal organoids also suggest a potential mechanism for AUD-mediated changes in the gut barrier function during HIV; the intestines of HIV+ individuals have low resilience to alcohol induced intestinal barrier disruption caused by high levels of oxidative stress. Finally, our preliminary data also suggest a potential approach to enhance the integrity of the intestinal barrier and reduce gut derived inflammation in people living with HIV with\u002Fwithout AUD- short chain fatty acid prebiotics. These prebiotics prevent alcohol mediated adverse effects on the intestinal barrier and inflammation by preventing oxidative stress. These prebiotics are safe and decrease gut inflammation in humans.\n\n40 HIV+ ART+ (20 AUD- and 20 AUD +), will be recruited for a prebiotic intervention. This is a proof-of-concept intervention study to establish a causal link between microbiota-gut and HIV pathology during ART by asking whether modifying microbiota and gut milieu impacts intestinal barrier function, systemic inflammation, and brain pathology in HIV+ people. Participants will complete three in-person clinic visits and four virtual check-in visits during this 8 week study. This study uses a crossover design. At baseline, participants will be randomized to receive either a prebiotic or a placebo for the first intervention period. After completing this period, participants will cross over to receive the alternate study product for the second intervention period, allowing each participant to serve as their own control. These participants are part of the larger observation study (n=160), which will test the hypothesis that intestines from HIV+ individuals have lower resilience to alcohol mediated gut barrier disruption than intestines from HIV-negative controls. New participants will also be recruited. Blood, urine, and stool, will be collected from participants to compare intestinal barrier integrity, system and gut inflammation, immune activation, oxidative stress, microbiome\u002Fmetabolome. and HIV reservois.",[490,491],"Alcohol Use Disorder","Human Immunodeficiency Virus","2026-06-02",{"date":219,"type":34},{"date":495,"type":34},"2024-03-05",{"date":497,"type":22},"2029-08-31",{"name":40,"class":41},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":23,"phases":508,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":42},"100559905","early-phase-1-evaluating-the-efficacy-of-combined-cognitive-processing-therapy-and-stellate-ganglion-blocks-for-ptsd-100559905","NCT06570213","Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD","Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Are 18 years or older\n* Are fluent in English\n* Have experienced a Criterion A traumatic event during their lifetime\n* Have a PTSD diagnosis verified via the Clinician Administered PTSD Scale for DSM-5\n* Have not previously received a Stellate Ganglion Block\n* Have a smartphone that they can use for the entire duration of the study\n* Are willing and able to receive 2 injections (SGB or placebo) 2 weeks apart at the Rush Pain Clinic\n* Are willing and able to participate in daily Cognitive Processing Therapy or Daily Monitoring over the course of one week\n* Are willing and able to complete self-report measures and clinician-rated assessments at multiple time points over the course of the study\n\nExclusion Criteria:\n\n* The traumatic event occurred in the past month\n* They are currently suicidal or homicidal (i.e., plan and intent)\n* They have unmanaged psychosis or mania\n* They have not been on a stable dose of psychotropic medication for at least one month by the time of the baseline assessment or are planning to change their medications within 3 months of starting their participation in the study\n* They have completed an evidence-based cognitive behavioral PTSD treatment (e.g., Cognitive Processing Therapy or Prolonged Exposure) in the past 3 months or are currently receiving an evidence-based PTSD treatment\n* They have an intellectual disability or significant cognitive impairment that would prevent them from engaging fully in treatment\n* They are currently on any blood-thinning medications or have a coagulopathy -They have any of the following conditions: a recent myocardial infarction, glaucoma, a pre- existing contralateral nerve palsy, severe emphysema, or a cardiac conduction blockade.\n* They are allergic to any of the medications injected (i.e., ropivacaine, lidocaine, propofol)\n* They have an active infection\n* They have a serious or unstable medical illness or instability for which hospitalization may be likely within the next year\n* They have a visual or auditory impairment that would prevent them from fully participating in study activities\n* They are involved with current legal actions related to the traumatic event that is anticipated to be targeted during treatment\n* They have substance dependence that, in the judgment of the Principal Investigator, may require hospitalization if substances were discontinued.\n* Subjects who, at the time of consent, appear to have extenuating life circumstances (e.g., unstable housing, no internet access, etc.) which, in the judgment of the Principal Investigator, could affect the ability to deliver the intervention with fidelity",{"count":507,"type":22},270,[509],"EARLY_PHASE1","The purpose of this study is to understand if we can improve the treatment for posttraumatic stress disorder (PTSD). We are looking into whether the combination of Stellate Ganglion Block (SGB) treatment and Cognitive Processing Therapy (CPT) can reduce symptoms of PTSD. CPT is a trauma-focused talk therapy that can help identify and challenge unhelpful trauma-related beliefs about oneself, others, and the world. It is known to be a highly effective talk therapy for PTSD. SGB treatment is a procedure involving an injection of local anesthetic into a bundle of nerves located in the neck that is part of the sympathetic nervous system which controls our body's response to stressful situations and blocks pain.\n\nThe proposed project will systematically test whether combining CPT with SGB produces greater PTSD symptom reductions and functional improvements in the short- and longer-term up to 6-months follow-up compared to CPT (+Placebo) or SGB (+Daily Monitoring) alone.",[512],"PTSD","2026-05-29",{"date":492,"type":34},{"date":516,"type":34},"2026-04-01",{"date":518,"type":22},"2029-12-31",{"name":40,"class":41},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":526,"maxAge":527,"enrollmentInfo":528,"targetDuration":4,"studyType":23,"phases":529,"briefSummary":530,"conditions":531,"keywords":533,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":42},"100610236","roam-oa-functional-and-patient-reported-outcomes-wearing-a-knee-brace-for-unicompartmental-oa-100610236","NCT07224958","ROAM OA: Functional and Patient Reported Outcomes Wearing a Knee Brace for Unicompartmental OA","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Age 40-85 years.\n* BMI ≤ 35.\n* Physician-diagnosed medial compartment knee osteoarthritis.\n* Visual Analog Scale (VAS) walking pain ≥ 4.\n* Willing to wear assigned brace ≥ 4 hours\u002Fday.\n* Able to walk independently for 20 minutes unaided.\n* Stable pain medication regimen ≥ 4 weeks.\n* ≥3 months since last hyaluronic acid (HA), platelet-rich plasma (PRP), or steroid injection.\n\nExclusion Criteria:\n\n* Lateral or patellofemoral osteoarthritis.\n* Prior knee replacement.\n* Significant ligament injury or acute lower limb injury.\n* Neurological condition affecting gait.\n* Severe psychiatric or neurological disorder affecting pain perception.\n* Skin condition or allergy preventing brace use.\n* Current use of another brace or assistive device.\n* Recent opioid or corticosteroid use (\\\u003C4 weeks).\n* Pregnant.\n\nExclusion Criteria:\n\n\\-","40 Years","85 Years",{"count":438,"type":22},[55],"The aim of this study is to conduct a comparative evaluation of the ROAM OA Single Upright Brace and the Ossur Unloader One Knee Brace in subjects with medial compartment osteoarthritis. The focus is on comparing the immediate and short-term biomechanical effects of these braces on knee adduction moments and spatiotemporal gait parameters, as well as assessing the long-term efficacy of the ROAM OA brace in improving pain and functional outcomes for individuals with osteoarthritis.",[532],"Knee Osteoarthritis",[534,535],"knee brace","gait analysis","2026-05-10",{"date":538,"type":34},"2026-05-12",{"date":540,"type":34},"2026-04-27",{"date":542,"type":22},"2027-04",{"name":40,"class":41},{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":23,"phases":552,"briefSummary":553,"conditions":554,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":451},"100369439","phase-4-dual-mobility-acetabular-cups-in-revision-tja-100369439","NCT04090359","Dual Mobility Acetabular Cups in Revision TJA","Inclusion Criteria:\n\n* Any patient older than 18 years of age scheduled for a revision THA, including revision of both components, conversion of a hip resurfacing to THA, conversion of a hemiarthroplasty to THA, and revision of single components which allow implantation of dual-mobility bearings. In addition, patients undergoing reimplantation of a total hip arthroplasty following a two-stage revision for periprosthetic infection will also be included. Only patients with an acetabular shell diameter capable of accommodating at least a 36mm femoral head will be included.\n\nExclusion Criteria:\n\n* Less than 18 years of age, primary THA,\n* conversion of non-arthroplasty femoral neck fracture fixation to THA,\n* patients unwilling to participate.\n* patients where the surgeon makes the intraoperative decision to use a constrained liner will be excluded.",{"count":551,"type":22},322,[162],"The aim of this study is to the compare clinical outcomes of patients undergoing a revision total hip arthroplasty (THA) with the use of a dual mobility bearing versus a single bearing design with the use of a large femoral head (36mm or 40mm). We hypothesize the use of dual-mobility components in revision THA will be associated with a lower dislocation rate in the first year following surgery.",[555],"Dislocation, Hip","2026-04-29",{"date":558,"type":34},"2026-05-05",{"date":560,"type":34},"2017-09-01",{"date":562,"type":22},"2036-11-01",{"name":40,"class":41},{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":23,"phases":573,"briefSummary":574,"conditions":575,"keywords":577,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":451},"100626055","nurse-led-ptsd-treatment-in-primary-care-100626055","NCT07430657","Nurse-Led PTSD Treatment in Primary Care","A Hybrid Implementation-Effectiveness Trial of Nurse-Delivered Post-Traumatic Stress Disorder Treatment in Primary Care","Inclusion Criteria:\n\n* o PTSD + trauma exposure (PCL-5 score ≥28, plus trauma endorsed on LEC-5\u002FCAPS)\n\n  * Life-threatening CV event in the last 90 days (including myocardial infarction\u002Fheart attack, acute cerebrovascular accident\u002Fstroke, sudden cardiac arrest, acute decompensated heart failure, or life-threatening arrhythmia requiring cardioversion or defibrillation).\n  * Primary care patient at Rush University Medical Center\n\nExclusion Criteria:\n\n* o Safety risk (documented suicidal ideation\u002Fneed for acute psychiatric care)\n\n  * NET conflict (actively receiving psychotherapy\u002FPTSD treatment)\n  * Cognitive\u002Fdecisional non-capacity (University of California, San Diego Brief Assessment of Capacity to Consent \\[UBACC\\] ≤ 14.5)",{"count":572,"type":22},100,[55],"Purpose of the Study Post-traumatic stress disorder (PTSD) is a common and serious condition, but many people cannot get the help they need because there are not enough mental health specialists (like psychologists or psychiatrists) available. This study is testing a new program called NurseNET. The goal of NurseNET is to train nurses to provide a proven, short-term trauma treatment called Narrative Exposure Therapy (NET).\n\nWhy This Study is Important Most people see their nurse or doctor for health concerns. Because nurses are highly trusted and already work on the front lines of healthcare, they may be in the best position to offer PTSD treatment quickly and conveniently. This study aims to see if nurse-led care can bridge the gap between patients and the treatment they deserve.\n\nWhat the Study Involves Researchers will enroll 100 participants who have symptoms of PTSD. Participants will work with a trained nurse in a primary care setting to complete the NurseNET program.\n\nThe Treatment: The program consists of 4 to 6 sessions. During these sessions, the nurse helps the patient talk through their life story and process difficult memories in a safe, supportive way.\n\nWhat We Are Measuring: The research team will look at several factors to see if the program is successful:\n\nEffectiveness: Do PTSD symptoms improve after working with the nurse?\n\nFeasibility and Acceptability: Do patients and nurses find this type of care easy to use and helpful?\n\nHealth Impact: Since PTSD is linked to heart health, the study will also look at whether the treatment improves things like blood pressure or physical activity levels.\n\nGoal of the Research By the end of this study, researchers hope to show that nurses can safely and effectively provide trauma care. If successful, this model could be used across the United States to make PTSD treatment much easier to access for everyone.",[576],"Post Traumatic Stress Disorder PTSD",[578,579,580],"post traumatic stress disorder","primary care","nurse","2026-04-23",{"date":556,"type":34},{"date":584,"type":34},"2026-03-30",{"date":586,"type":22},"2029-09",{"name":40,"class":41},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":23,"phases":596,"briefSummary":597,"conditions":598,"keywords":599,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":42},"100635027","mobilizing-community-hypertension-access-pilot-100635027","NCT07547345","Mobilizing Community Hypertension Access Pilot","Live Healthy Chicago - Community Pilot","Inclusion Criteria:\n\n* Adults 18 years or older\n* Record of two blood pressure readings of SBP\\>130 on two separate occasions (days) within the past 3 months\n\nExclusion Criteria:\n\n* Person is receiving dialysis\n* Person has had a heart or kidney transplant\n* Person is pregnant",{"count":388,"type":22},[55],"The Live Healthy Chicago (LHC) Community Pilot is a prospective, community-based study evaluating the feasibility, effectiveness, and economic impact of a pharmacist-led hypertension management program delivered in trusted community settings on the West and South Sides of Chicago. Adults with uncontrolled hypertension will be identified and enrolled through community-based organizations, where a mobile clinical team-including community health workers, a pharmacist, and a registered nurse-will provide blood pressure screening, medication management, health education, and care coordination over a 3-month period. The study will assess participant engagement and acceptability, changes in systolic blood pressure. This pilot aims to address disparities in hypertension control by improving access to care in underserved communities and informing scalable, community-based models of chronic disease management.",[392],[392,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617,618],"Blood Pressure Control","Cardiovascular Disease Prevention","Pharmacist-Led Care","Community-Based Intervention","Community Health Workers","Mobile Health Services","Medication Management","Medication Adherence","Health Disparities","Underserved Populations","Social Determinants of Health","Care Coordination","Chronic Disease Management","Preventive Cardiology","Urban Health","Feasibility Study","Pilot Study","Cost-Effectiveness","Population Health","2026-04-17",{"date":581,"type":34},{"date":622,"type":34},"2026-02-20",{"date":624,"type":22},"2027-03",{"name":40,"class":41},{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":4,"eligibilityCriteria":632,"healthyVolunteers":50,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":23,"phases":635,"briefSummary":636,"conditions":637,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":42},"100411574","neurovision-vs-standard-neuromonitoring-100411574","NCT04639297","NeuroVision vs Standard Neuromonitoring","NeruoVision Versus Standard Hospital Neuromonitoring, Influence on the Rate of Neurologic Injury Following Spine Surgery? A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients undergoing a primary single or multilevel lateral spinal surgery procedures for degenerative pathology Diagnosis: myelopathy, radiculopathy, myeloradiculopathy, central stenosis, foraminal stenosis herniated nucleus pulposus, degenerative disc disease, spondylosis, and osteophytic complexes\n* Patients able to provide informed consent\n\nExclusion Criteria:\n\n* Active infection\n* Active or history of malignancy\n* Spinal traumatic injury within the past 2 years",{"count":634,"type":22},148,[55],"The purpose of this study is to perform a prospective, randomized, controlled clinical trial to assess the utility of IONM in patients undergoing primary, single or multilevel lateral spinal procedures. Subjects will be randomized to undergo a lateral spine surgery with the use of NeuroVision® IONM or conventional hospital based IONM to assess incidence of new-onset neurological injury.",[638],"Neurologic Deficits",{"date":640,"type":34},"2026-04-07",{"date":642,"type":34},"2020-09-28",{"date":644,"type":22},"2027-12-20",{"name":40,"class":41},""]